Top Markets
#1 Akedo Akedo +71.59%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +48.61%
#4 Cross Cross +34.10%
#5 Black Phoenix Black Phoenix +33.95%
#6 Cap Cap +29.61%
#7 Velvet Velvet +26.32%
#8 Ravencoin Ravencoin +17.91%
#9 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +16.35%
#10 DoubleZero DoubleZero +12.07%
Coin of the day
Akedo Akedo
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Hepion Pharmaceuticals, Inc. Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals, Inc.

HEPA
Rangering i aksjer #39072
Hepion Pharmaceuticals, Inc., a U.S.-based biopharmaceutical entity, is... Hepion Pharmaceuticals, Inc., a U.S.-based biopharmaceutical entity, is dedicated to developing therapeutic interventions for chronic hepatic ailments. Central to their efforts is Rencofilstat, a cyclophilin inhibitor that has successfully concluded Phase 2a clinical trials. This compound operates by disrupting multiple pathological pathways implicated in the worsening of liver disease. It is currently progressing through clinical development for non-alcoholic steatohepatitis (NASH) and is additionally being explored in nonclinical research for its potential to reduce liver fibrosis and lessen hepatocellular carcinoma tumor loads in experimental models of NASH. Moreover, Rencofilstat has exhibited antiviral properties against hepatitis B, C, and D viruses through diverse mechanisms. The company, established in 2013 and situated in Edison, New Jersey, rebranded as Hepion Pharmaceuticals, Inc. in July 2019, having previously operated as ContraVir Pharmaceuticals, Inc.
Aksjekurs
$0.073
Markedsverdi
$849.99K
Endring (1 dag)
4.29%
Endring (1 år)
21.67%
Land
US
Handel Hepion Pharmaceuticals, Inc. (HEPA)

Kategori

Healthcare
Inntekter for Hepion Pharmaceuticals, Inc. (HEPA)
Inntekter i Aug 2026 TTM: 0
Ifølge de nyeste økonomiske rapportene til Hepion Pharmaceuticals, Inc. er selskapets nåværende inntekter (TTM) 0. I 2026 hadde selskapet inntekter på 0 lik inntektene i 2026, som var 0. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for Hepion Pharmaceuticals, Inc. fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE